Medpace Holdings (MEDP) closed at $653.94 on November 13, 2026, down 0.4% from the previous close, on volume of 100,641 shares (30-day average 282,823).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 30, 2026 | Calendar Put Spread | 15-Jan : 19-Mar-27 220 P | 910 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Medpace lifts profitability in Q3 2026 as EBITDA margin reaches 24.0% and backlog tops $3.17B
Market Chameleon (Thu, 22-Oct 5:53 AM ET)
Medpace Holdings, Inc. Reports Third Quarter 2026 Results
Business Wire (Wed, 21-Oct 4:15 PM ET)
Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026
Business Wire (Tue, 22-Sep 4:05 PM ET)
Globe Newswire (Mon, 31-Aug 8:00 AM ET)
Medpace Posts 17% Revenue Growth and Raises 2026 Forecast—Profit Margins and Cash Flow Remain Strong
Market Chameleon (Thu, 23-Jul 7:44 AM ET)
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Medpace Holdings trades on the NASDAQ stock market under the symbol MEDP.
As of November 13, 2026, MEDP stock price declined to $653.94 with 100,641 million shares trading.
MEDP has a beta of 0.29, meaning it tends to be less sensitive to market movements. MEDP has a correlation of 0.01 to the broad based SPY ETF.
MEDP has a market cap of $18.29 billion. This is considered a Large Cap stock.
Last quarter Medpace Holdings reported $716 million in Revenue and $4.84 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.38.
In the last 3 years, MEDP traded as high as $693.97 and as low as $250.05.
The top ETF exchange traded funds that MEDP belongs to (by Net Assets): IJH, VTI, VB, XMHQ, VBK.
MEDP has underperformed the market in the last year with a return of +10.6%, while SPY returned +13.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MEDP shares. However, MEDP has outperformed the market in the last 3 month and 2 week periods, returning +12.4% and +0.3%, while SPY returned -2.8% and -0.2%, respectively. This indicates MEDP has been having a stronger performance recently.
MEDP support price is $641.15 and resistance is $672.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MEDP shares will trade within this expected range on the day.
